6.510USD-7.13%Mkt Cap: 432.45M USDP/E: —Last update: 2026-06-01
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United St…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap432.45M USD
Enterprise Value133.65M USD
Revenue (TTM)—
Gross Profit-56.78M USD
Net Income (TTM)-74.88M USD
Revenue/Share—
Last Price6.510 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.21
PEG—
EV/EBITDA-1.57
EV/Revenue—
P/S—
P/B1.38
EPS (TTM)-1.15
EPS (Forward)-1.33
52W Range
5.8806% of range15.74
52W High15.74 USD
52W Low5.880 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.46%
ROA-20.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.06M USD
CapEx (TTM)314.00K USD
FCF Margin—
FCF Yield-8.73%
Net Debt-327.45M USD
Net Debt/EBITDA3.84
Balance Sheet
Debt/Equity0.02
Current Ratio34.33
Quick Ratio33.97
Book Value/Sh5.004 USD
Cash/Share5.002 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)18.90 USD
Target Range8.000 USD – 25.00 USD
# Analysts10
Ownership
Shares Out.66.63M
Float47.97M
Insiders3.86%
Institutions108.04%
Short Interest
Short Ratio10.7d
Short % Float11.84%
Short % Out.11.71%
Shares Short7.80M
Short (prev mo.)7.55M
Technical
SMA 507.236 (-10.0%)
SMA 2008.801 (-26.0%)
Beta3.01
S&P 52W Chg27.94%
Avg Vol (30d)578.75K
Avg Vol (10d)423.29K
Technical Indicators
RSI (14)50.7
MACD-0.1992
MACD Signal-0.2630
MACD Hist.+0.0639
BB Upper7.548 USD
BB Middle6.811 USD
BB Lower6.074 USD
BB Width21.65%
ATR (14)0.3937 USD
Vol Ratio (20d)0.42x